Lyra Therapeutics Inc
Research Lyra Therapeutics Inc (LYRA) on Bullrun: market cap USD 843.08K. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerLYRA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 843.08K
- Financial periodFY2025
- RevenueUSD 398.00K
- Revenue growth-74.1%
- Net income-USD 28.92M
- Free cash flow-USD 28.98M
Valuation Snapshot
latest market cap is USD 843.08K.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 398.00K | -USD 28.92M | -USD 28.98M | n/a | -18.62 | USD 15.89M | USD 30.26M | -USD 10.72M |
| FY2024 | USD 1.53M | -USD 93.44M | -USD 72.35M | n/a | -71.75 | USD 40.58M | USD 34.38M | USD 11.59M |
| FY2023 | USD 1.56M | -USD 62.68M | -USD 64.35M | n/a | -1.26 | USD 22.35M | USD 26.88M | USD 89.42M |
| FY2022 | USD 1.36M | -USD 55.28M | -USD 43.55M | n/a | -1.83 | USD 32.55M | USD 929.00K | USD 80.75M |
| FY2021 | USD 285.00K | -USD 43.51M | -USD 29.21M | n/a | -3.35 | USD 45.75M | n/a | USD 34.32M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-07-30 | USD 843.08K | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 4.08M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 13.50M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 275.44M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 99.93M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 56.70M | n/a | n/a | n/a |
About Lyra Therapeutics Inc
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS);
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Lyra Therapeutics Inc's market cap?
Lyra Therapeutics Inc's market capitalization is USD 843.08K.
What does Lyra Therapeutics Inc do?
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration.